Emapalumab for Multiple Myeloma

This trial explores whether emapalumab, an immunotherapy drug, can prevent serious side effects like cytokine release syndrome (CRS) and neurotoxicity in patients with blood cancers such as lymphoma or multiple myeloma who receive bispecific antibody therapy. The goal is to determine if emapalumab effectively and safely reduces these risks. It suits individuals with relapsed or hard-to-treat large B-cell lymphoma or multiple myeloma who have tried other treatments and are scheduled for bispecific antibody therapy. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants, providing an opportunity to contribute to significant findings.

The trial requires a break from certain medications before starting the bispecific antibody therapy. You need to wait at least 2 weeks or 5 half-lives (whichever is shorter) after your last systemic therapy, except for immune checkpoint therapy, which requires a longer break. Steroids need a 7-day break.

Research has shown that emapalumab has been used safely in other conditions. One study found that serious side effects occurred in 53% of patients, with infections and stomach bleeding being common issues. However, other research has not identified any new safety concerns. The FDA has already approved emapalumab for treating macrophage activation syndrome, indicating it has passed rigorous safety tests. Although serious side effects have been reported, its approval for other uses may provide some reassurance about its safety.¹²³⁴⁵

Emapalumab is unique because it targets the immune protein interferon gamma (IFN-γ), which plays a role in inflammation and immune response. Unlike current treatments for multiple myeloma, which often include therapies like proteasome inhibitors and immunomodulatory drugs, Emapalumab offers a novel approach by specifically inhibiting IFN-γ. Researchers are excited about Emapalumab because this targeted action could potentially reduce inflammation and improve outcomes for patients, offering a new line of attack against the disease.

Research has shown that emapalumab may help treat immune system issues. In studies on primary hemophagocytic lymphohistiocytosis (HLH), emapalumab helped 63% of patients improve, indicating its potential effectiveness in managing immune problems. Specifically, in severe cases of cytokine release syndrome (CRS), emapalumab improved patient health quickly, within 12 hours. This trial will investigate emapalumab as a prophylactic treatment to potentially prevent CRS and nerve damage in patients receiving certain treatments for blood cancers, such as multiple myeloma.¹⁶⁷⁸⁹